Juno Therapeutics (JUNO) PT Lowered to $34 at Maxim Group

SunTrust Robinson Humphrey Downgrades Juno Therapeutics (JUNO) to Hold

SunTrust Robinson Humphrey downgraded Juno Therapeutics (NASDAQ: JUNO) from Buy to Hold with a price target of $25.00 (from $48.00) after the ROCKET study evaluating JCAR015 in no-option Adult ALL was placed on clinical hold for the second time.

The analyst sees reduced visibility and increased... More

Unusual 11 Midday Movers 11/23: (ESEA) (SINO) (GLBS) Higher; (JUNO) (SKLN) (ACIU) Lower

Euroseas Ltd. (Nasdaq: ESEA) 56.1% HIGHER; announced that it signed a memorandum of agreement to purchase the M/V Capetan Tassos, a Panamax size drybulk carrier of 75,100 dwt built in 2000 in Japan for approximately $4.4 million. The vessel is expected to be delivered to the Company in January 2017. The Company also announced that it reached an agreement with a company affiliated with its CEO to draw a $2 million loan to finance working capital needs. Interest on the loan is payable quarterly, and there are no principal repayments until January 2018 when the loan... More

Juno Therapeutics (JUNO) Shares to Reflect 'Increased Level of Uncertainty' - Leerink

Leerink Partners analyst Michael Schmidt weighed in on Juno Therapeutics (NASDAQ: JUNO) after the company announced that it placed the pivotal "ROCKET" trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (ALL) on a clinical hold after 2 additional patients died due... More

Streetinsider.com's Hot Lunchtime Reads 11/23: (JUNO) (AMZN) (AXON) (LLY)

The following is a list of notable articles to help get you through the lunch hour:Amazon.com (AMZN) Said Planning New Video Chat Service Following Recent Acquisition ->... More

BTIG Remains Neutral on Juno Therapeutics (JUNO); Says JCAR015 Will Have 'Limited Impact' on Ests

BTIG affirms Juno Therapeutics Inc. (Nasdaq: JUNO) at Neutral after the company announced that the ROCKET... More

Roth Capital Keeps Lion Bio (LBIO) at 'Buy' Following Juno's (JUNO) ROCKET Study Update

Roth Capital affirms Lion Biotechnologies (Nasdaq: LBIO) at Buy with a price target of $15 following ROCKET study news from Juno Therapeutics (Nasdaq: JUNO) on Wednesday. The firm is confident in Lion Bio's TIL therapies.

Analyst Joseph Pantginis commented today, The previous Phase I study of... More

Pre-Open Stock Movers 11/23: (MDGS) (VEEV) (BLXT) Higher; (JUNO) (LLY) (URBN) Lower (more...)

Today's Pre-Open Stock Movers

Medigus Ltd. (NASDAQ: MDGS) 41.6% HIGHER; announced a distribution agreement in Italy with INNOVAMEDICA S.p.A, a privately owned distributor of minimally invasive medical devices. Under terms of the four-year agreement which will take effect January 1st 2017, INNOVAMEDICA S.p.A. will be required to purchase at least 1M of Medigus Ultrasonic Surgical Endostapler (MUSE) equipment over the course of the agreement.

Euroseas Ltd. (Nasdaq:... More

Juno Therapeutics (JUNO) CEO Bishop: Second JCAR015 Patient with Brain Swelling has Died - Conf. call

Juno Therapeutics (NASDAQ: JUNO) CEO Hans Bishop said that the second JCAR015 patient with brain swelling has died, according to the company's conference call on Wednesday. Patients who died were treated last week, the CEO noted.

The company has treated 12 patients since... More

bluebird bio (BLUE) Falls 5% on Juno Clinical Hold

bluebird bio (NASDAQ: BLUE) is trading down after peer Juno Therapeutics, Inc. (Nasdaq: JUNO) announced that it has voluntarily placed on hold the Phase II clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute... More

Juno Therapeutics (JUNO) Sinks 40% as Trading Resumes after Clinical Hold

Juno Therapeutics (NASDAQ: JUNO) resumed trading down 40% after the company announced that it has voluntarily placed on hold the Phase II clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia, known as the ROCKET trial. The clinical... More

Juno Therapeutics (JUNO) to Resume Trading at 8:30AM ET after Clinical Hold Announced

Juno Therapeutics (NASDAQ: JUNO) set to resume trading at 8:30AM ET after it voluntarily placed on hold the Phase II clinical trial of JCAR015

Kite Pharma (KITE) on Watch as Juno Trial Placed on Clinical Hold

Kite Pharma (NASDAQ: KITE) on watch as Juno Therapeutics, Inc. (Nasdaq: JUNO) announced that it has voluntarily placed on hold the Phase II clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic... More

Juno Therapeutics (JUNO) Halted for News Release

Juno Therapeutics (NASDAQ: JUNO) Halted for News Release

Juno Therapeutics (JUNO) JCAR015 Phase II ROCKET Trial Placed on Clinical Hold

Juno Therapeutics, Inc. (Nasdaq: JUNO) announced that it has voluntarily placed on hold the Phase II clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia, known as the ROCKET trial. The clinical hold was initiated after two patients suffered cerebral edema... More